Can Gilead make remdesivir pay?
Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.
Covid-19 antibody tests face a very specific problem
With the prevalence of coronavirus infection running at about 5%, test manufacturers and regulators alike will have to guard against false positives.
What to look for in upcoming Covid-19 trial readouts
Industry-sponsored clinical studies against the new coronavirus have proliferated, as have their designs and efficacy measures.
The long path to an effective coronavirus vaccine
What is biopharma doing to develop vaccines against Covid-19, and what are the properties of each approach? Vantage takes a look.
Joint makers report pandemic pain
Sales of implants are set to fall sharply as non-urgent procedures are deferred.
A Covid-19 threat to business acquisitions
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
The scramble to reinvent the ventilator
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
Merck’s cough success highlights pipeline hopes
Good news for patients whose cough is not caused by Covid-19: Merck’s chronic cough pill is a step closer to market. But tolerability questions remain.
Biotech’s balancing act amid Covid-19 delays
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.
